Events

AusBiotech, Cell Therapies, Research Strategies Australia and MTPConnect have made a joint submission to the parliamentary inquiry into the opportunity for Australia's manufacturing industry to harness the potential of emerging cell and gene therapies, or regenerative medicines.

Clinical stage immuno-oncology company Imugene (ASX:IMU) has announced it has received a notice of grant from the Japanese Patent Office for its application to protect its HER-Vaxx immunotherapy.

Rhythm Biosciences (ASX:RHY) has announced the appointment of a new chair with the resignation of incumbent Shane Tanner.

Experts have released research that says drug repurposing is no quick fix for developing new treatments for COVID-19 with inherent dangers and pitfalls in translating drugs to treat the virus.

Monash University has announced it will establish a Victorian Health Innovation Centre, including a flagship cardiovascular disease-focused research accelerator, HeartLabs, as well as a new focal point for clinical trials.

AusBiotech is seeking member feedback as it responds to the Department of Health’s Review of the National Medicines Policy.

Clinical-stage biopharmaceutical company Bionomics (ASX:BNO) has announced it will proceed with evaluating its lead clinical compound, BNC210, for the treatment of acute Social Anxiety Disorder.

Certa Therapeutics has announced the launch of a Phase 2 trial in Australia for a potential new treatment for Diffuse Systemic Scleroderma.

Monash University researchers have shown for the first time that mesenteric lymphatic dysfunction is a potential cause of and therapeutic target for obesity and insulin resistance.

Australia has another new industry minister following the resignation of Christian Porter after just six months in the portfolio.

AusBiotech and Medicines Australia have released a joint statement urging the Australian Government to not support a proposed patent waiver for COVID-19 vaccines and therapies, as it will not help global vaccination.

Clinical-stage cell therapy company Chimeric Therapeutics (ASX:CHM) has announced the appointment of three highly regarded experts to its Cellular Immunotherapy Scientific Advisory Board.